Active surveillance of antibiotic resistance prevalence in urinary tract and skin infections in the outpatient setting

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages 1845-1851

  Kronenberg, A ^a   Koenig, S ^a   Droz, S ^a   Muhlemann K ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Active; Multiresistance; Skin infection; Surveillance; Switzerland; Urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM; EXTENDED SPECTRUM BETA LACTAMASE; NORFLOXACIN; QUINOLONE;

ADOLESCENT; ADULT; AMBULATORY CARE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SENSITIVITY; ESCHERICHIA COLI; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; SWITZERLAND; URINALYSIS; URINARY TRACT INFECTION;

ESCHERICHIA COLI; STAPHYLOCOCCUS AUREUS;

EID: 81255138194     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03519.x     Document Type: Article

References (30)

1. Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ. Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health 2006; 2: 6.
2. Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14: 413-420.
3. Rodriguez-Bano J, Alcala JC, Cisneros JM et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-1902.
4. Harbarth S, Emonet S. Navigating the world wide web in search of resources on antimicrobial resistance. Clin Infect Dis 2006; 43: 72-78.
5. Durham LK, Ge M, Cuccia AJ, Quinn JP. Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli. Eur J Clin Microbiol Infect Dis 2010; 29: 353-356.
6. Pitout JD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary health region from 2000 to 2007: emergence of clone st131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009; 53: 2846-2851.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne, PA: CLSI, 2008.
8. Coudron PE, Moland ES, Sanders CC. Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a Veterans Medical Center: seek and you may find. J Clin Microbiol 1997; 35: 2593-2597.
9. Aspevall O, Hallander H, Gant V, Kouri T. European guidelines for urinalysis: a collaborative document produced by European clinical microbiologists and clinical chemists under ECLM in collaboration with ESCMID. Clin Microbiol Infect 2001; 7: 173-178.
10. Scottish intercollegiate guidelines network. Management of suspected bacterial urinary tract infection in adults. A national clinical guideline. Scottish intercollegiate guidelines network. 2006. Available at:
11. Grabe M, Bishop MC, Bjerklund-Johansen TE et al. Guidelines on urological infections. European Association of Urology 2009. Available at:
12. Gradwohl SE, Chenoweth CE, Fondue RK, Van Harrison R, Zoschnick LB. Guidelines for clinical care. Urinary tract infection. University of Michigan Health System, 2005. Available at:
13. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: a population-based assessment. Infection 2007; 35: 150-153.
14. Schito GC, Naber KG, Botto H et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34: 407-413.
15. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54: 1164-1175.
16. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004; 39: 75-80.
17. EARSS annual report 2008. Available at: (last accessed 1 October 2010).
18. Kronenberg AZG, Piffaretti JC, Mühlemann K. Antibiotikaresistenzdaten der schweiz: Jetzt online. Schweiz Med Forum 2008; 8: 415-418.
19. Ferech M, Coenen S, Malhotra-Kumar S et al. European surveillance of antimicrobial consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother 2006; 58: 423-427.
20. Arpin C, Quentin C, Grobost F et al. Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother 2009; 63: 1205-1214.
21. Luzzaro F, Mezzatesta M, Mugnaioli C et al. Trends in production of extended-spectrum beta-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol 2006; 44: 1659-1664.
22. Andreu A, Planells I. Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study. Med Clin (Barc) 2008; 130: 481-486.
23. Yilmaz N, Agus N, Yurtsever SG et al. Prevalence and antimicrobial susceptibility of Escherichia coli in outpatient urinary isolates in Izmir, Turkey. Med Sci Monit 2009; 15: PI61-PI65.
24. Lartigue MF, Zinsius C, Wenger A, Bille J, Poirel L, Nordmann P. Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. Antimicrob Agents Chemother 2007; 51: 2855-2860.
25. Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli producing extended-spectrum beta-lactamases: importance of community isolates with blactx-m genes. Clin Infect Dis 2004; 38: 1736-1741.
26. Colodner R, Rock W, Chazan B et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23: 163-167.
27. Rodriguez-Bano J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
28. Ben-Ami R, Rodriguez-Bano J, Arslan H et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-690.
29. Azap OK, Arslan H, Serefhanoglu K et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2009; 16: 147-151.
30. Aramburu C, Harbarth S, Liassine N et al. Community-acquired methicillin-resistant Staphylococcus aureus in Switzerland: first surveillance report. Euro Surveill 2006; 11: 42-43.